Login to Your Account



High tide for protides: Nucana Biomed pulls in $57M series B

By Cormac Sheridan
Staff Writer

Thursday, April 10, 2014

Buoyed by unexpectedly early signs of robust clinical efficacy for its lead protide cancer drug Acelarin (NUC-1031), Nucana Biomed Ltd. raised $57 million in a series B round to accelerate its development and to advance several others into the clinic.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription